Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721250 | 0.87 | HIF1A (0.56) | MIFHIF1ACYP2A6TRPA1CYP2E1 | |
| SCHEMBL10325242 | 0.87 | TRPA1 (0.48) | MIFHIF1ACYP2A6TRPA1CYP2E1 | |
| SCHEMBL5466467 | 0.86 | HTR3A (0.55) | MIFSMN1; SMN2HTR2AADRA1ASLC6A3 | |
| SCHEMBL9819810 | 0.84 | MIF (0.55) | MIFHTR3AMAPTMAOAMAOB | |
| SCHEMBL1653 | 0.84 | ALDH1A1 (0.55) | MIFCYP2A6TRPA1ALDH1A1HPGD | |
| SCHEMBL9819801 | 0.82 | NAAA (0.56) | MIFHTR3AMAPTMAOAMAOB | |
| SCHEMBL9819788 | 0.82 | NAAA (0.56) | MIFHTR3AMAPTMAOAMAOB | |
| SCHEMBL2587464 | 0.82 | LTA4H (0.57) | HIF1ASMN1; SMN2LMNASLC6A2SLC6A3 | |
| Hydrogen Sulfide SCHEMBL5079696 | 0.81 | ALDH1A1 (0.52) | MIFCYP2A6TRPA1ALDH1A1HPGD | |
| SCHEMBL9120248 | 0.78 | HTR2A (0.48) | MIFCYP2A6TRPA1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | claimed |
| US-6737409-B2 | FOR CANCER THERAPY | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | claimed |
| EP-1412328-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | claimed |
| US-20030055002-A1 | Dolastatin 10 derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003008378-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | claimed |
| EP-1496052-B1 | NOVEL AMINOBENZAMIDE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-7253188-B2 | Aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-20050282815-A1 | Novel aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1496052-A1 | NOVEL AMINOBENZAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-5260446-A | Azo dye precursors | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-09 | — | — | US | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0546993-A1 | Water soluble triazine derivatives for the photochemical and thermal stabilisation of polyamide fiber materials | CIBA-GEIGY AG (CH) | 1993-06-16 | — | — | EP | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0433879-A2 | Aminothiazoles | BASF Aktiengesellschaft (DE) | 1991-06-26 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4423215-A | REACTING ESTER, SODIUM IODIDE, 4-PYRIDINEETHANESULFONIC ACID | AJINOMOTO COMPANY, INC. (JP) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055002-A1 | Dolastatin 10 derivatives | DAD1, DDOST, NPC1 | MIF 3783/4885HIF1A 3368/4885CYP2A6 2461/4885 |
| US-20050282815-A1 | Novel aminobenzamide derivative | GCKR, GCK, HK2 | MIF 4819/4885HIF1A 1538/4885CYP2A6 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.